In many countries, biomedical research funding organizations are placing greater emphasis on translating research findings into clinical trials that could improve patient care. For example, this is one of the goals of the NIH Roadmap initiative in the United States, where it has been called "T1 translation" (see Further information). Reflecting this emphasis by funding organizations, academic researchers are now often asked to indicate the significance of their findings with respect to human disease and/or to engage in pilot translational studies that demonstrate the utility of their laboratory discoveries for patients. Moreover, most investigators believe that it is part of their contract with society to engage in research that will benefit humanity.
Although the recent focus on translational research in academia is laudable and is undoubtedly in the best interest of society, this new direction does expose investigators to personal and professional risks that can negatively affect their careers. This commentary, which is written from the perspective of two academic investigators who have experienced the 'other side' of T1 translation and yet continue to engage in translational research, is intended to help investigators become aware of the limitations of clinical trials, as well as to provide guidance to investigators who choose to engage in translational research.
Limitations of clinical trials
When evaluating the outcome of a trial, it is critical to remember that all that it can assess is whether a particular drug, administered in a particular way, is effective in the selected patient population. Unfortunately, a negative or neutral clinical trial result is often interpreted as proof that the mechanistic hypothesis that formed the basis for the trial is incorrect. Although this is true in some instances, what is underappreciated is that clinical trials usually do not provide precise information on disease mechanisms or on the mechanisms of action of a given therapeutic agent. As most drugs have pleiotropic effects, and as many drugs have off-target effects that can offset their potential benefits, it is not always possible to infer mechanisms of disease from trial results. Thus, negative trial results do not always indicate that the hypothesis supporting the drug use is incorrect.
Indeed, in the early stages of clinical development, the benefit of a new therapy is not always apparent. For example, although beta-blockers are now the mainstay of therapy for nearly all patients with heart failure, the early use of beta-blockers for heart failure was attended by worsening heart failure 1 ; it took years for investigators to find the right dose of the right beta blocker, the proper tim ing to initiate therapy and the right patient populations. Unfortunately, we have learned to worship at the fount of evidence-based randomized clinical trials without always fully understanding what is actually being reflected by the results of these trials.
There are additional reasons why clinical trials fail that have little or nothing to do with the hypothesis that is being tested. The selection of patients for enrolment into clinical trials is not necessarily driven by scientific understanding of the appropriate patient population. Trial design can be affected by market forces; that is, a broader label for drug use may be needed for pharmaceutical companies to invest in developing the drug. Slow enrolment of patients into a trial may also lead to the eventual inclusion of patient populations beyond those expected to benefit most from the treatment. By including a broader patient population, the benefit of the drug may be muted and the overall results of the trial may be interpreted as negative, even though the drug may have worked in the appropriate subgroups.
Testing the wrong dose or administration schedule of an investigational drug is another common problem. Indeed, the translation of a drug dose from animal to human studies is not always clear because of unanticipated drug-food interactions, drug metabolism or other unanticipated variables that can reduce the potential benefit of a new agent. Finally, improvements in patient outcomes due to medical advances (such as new drugs or other advances in patient care) in the area in which the new agent is being developed could reduce its anticipated clinical impact if they occur during its development period. For example, mortality from myocardial infarction declined from 9% to 3% from 2000 to 2008, and so a trial of an investigational agent to treat myocardial infarction after 2008 would require a much larger sample size to show a significant benefit than a trial in 2000 (REF.
2).
Potential downsides for academic investigators
For investigators who engage in T1 research, there are downsides associated with the failure of associated clinical trials that are rarely discussed. First, the failure of a pivotal trial based on research that began in their laboratory is difficult personally and emotionally, especially if there is a suggestion that patients were harmed because of the treatment. Second, there is often the impression that because the results of a clinical trial are negative then their field of research is 'dead' , which can have an obvious negative impact on the investigator for future prospects regarding publications and funding. Given how often clinical trials fail 3 and how little clinical trials actually tell us about disease mechanisms, such judgments by the academic community are unfortunate and could impede the development of new ideas at a time when new therapies are greatly needed. Moreover, when a clinical trial is 'negative' there is often little interest and long delays in publishing the negative results, and crucial elements of the study are often not reported. Finally, many investigators may be bound by confidentiality agreements, and therefore are not at liberty to address the criticisms of their peers.
What can translational researchers do?
The development of new drugs is a long process and so involvement in it could represent a substantial proportion of an investigator's professional career. Investigators who choose to follow this pathway should understand that the likelihood of success in a Phase III trial is extremely low in some clinical areas 3 . However, this is not intended to imply that investigators who would like to engage in T1 research should abandon their research efforts or translational aspirations; rather, they should stay focused on the biology that formed the basis for their original hypothesis. The development of beta blockers for the treatment of heart failure is an inspiring example of how investigators followed the data and were not deterred by the initial discouraging results in clinical trials. Another example is provided by sildenafil, which is now approved for pulmonary arterial hypertension and erectile dysfunction, even though it initially failed in Phase II trials for hypertension and angina pectoris 4 . Second, translational investigators should familiarize themselves with the basic principles of clinical trial design to ensure that they are well positioned to have input into the design of Phase II trials that provide the 'go/no go' signals for progression into pivotal clinical trials. The high rate of failure in pivotal Phase III trials can be often traced back to problems with Phase II trial design, and so input from the investigator here may be particularly valuable. Thus, it is important for those who engage in T1 translational research to stay involved with their research ideas as they move into the clinic.
Third, the research community should insist on the timely and full publication of both negative and positive clinical trial data, and delay judgment until it becomes clear why the trial is negative. Although none of these suggestions will completely protect investigators from the inevitable disappointment when their ideas are not borne out in pivotal clinical trials, we hope that a clearer appreciation of the risks and benefits of engaging in translational research will encourage investigators to continue doing so.
